The effects of rosiglitazone on endothelin, nitric oxide and C-reactive protein in patients with impaired glucose tolerance
10.3969/j.issn.1006-6187.2010.01.015
- VernacularTitle:罗格列酮对糖耐量减低患者血浆内皮素、一氧化氮、C反应蛋白的影响
- Author:
Zhihao TANG
;
Hua YANG
- Publication Type:Journal Article
- Keywords:
Impaired glucose tolerance;
Rosiglitazone;
Endothelin;
Nitric oxide;
C-reactive protein
- From:
Chinese Journal of Diabetes
2010;18(1):51-53
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the changes in endothelin(ET), nitric oxide(NO) and C-reactive protein(CRP) before and after the rosiglitazone therapy in patients with impaired glucose tolerance(IGT). Methods 72 IGT patients were divided randomly into 2 groups: rosiglitazone group(n=45) and placebo group(n=27). 15 weeks later, the efficacy of rosiglitazone was compared. Results The levels of ET, CRP were decreased and NO increased significantly in rosiglitazone group compared with those before treatment (ET 54.8±10.0 pg/ml vs 72.8±24.3 pg/ml, P<0.01;CRP 4.58±0.38 mg/L vs 5.99± 0.85mg/L, P<0.01 ; NO 41.0±10.0 μmol/L. vs 31.3±9.0 μmol/L, P<0. 01)). However, the levels of ET,CRP and NO in placebo group did not change singnificantly (P>0. 05). Conclusions Rosiglitazone can singnificantly improve ET, NO, CRP level in IGT patients, which means an additional effect of rosiglitazone on the correlation of inflammation and endothelial disturbance.
